Home   About this service   Get the news  
+32 2 743 34 03

 Belgium  Other Countries
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...
UCB [BE0003739530/UCB]   
[20/10/2021]

UCB : UCB Media Room: UCB to license its AI technology that improves identification of Osteoporosis to ImageBiopsy Lab

https://mb.cision.com/Public/18595/logo/86a99b25f755738d_org.jpg UCB to license its AI technology that improves identification of Osteopo= rosis to ImageBiopsy Lab =C2=B7 ImageBiopsy Lab will further develop and launch an AIbased fracture= identification tool based on UCBdeveloped BoneBot AI technology which det= ects the presence of =E2=80=9Csilent=E2=80=9D or asymptomatic fractures... See more
 
UCB [BE0003739530/UCB]   
[18/10/2021]

UCB : UCB Media Room: Disposals of own shares

https://mb.cision.com/Public/18595/logo/86a99b25f755738d_org.jpg Disposals of own shares Brussels Belgium, 18 October 2021 =E2=80=93 20:00 CEST =E2=80=93 regula= ted information Disposal of own shares In accordance with article 8:6 of the Royal Decree executing the Belgian Co= de of Companies and Associations, UCB announces that, following exercises o= f stock options by members... See more
 
ECONOCOM GROUP [BE0974313455/ECONB]   
[18/10/2021]

ECONOCOM GROUP : Actions propres

Dans le cadre du programme de Rachat d'actions propres autorisé par l'Assemblée Générale des actionnaires le 19 mai 2020, Econocom Group SE a procédé, durant la période du 11/10/2021 au 17/10/2021, aux transactions suivantes sur l'action Econocom Group : Date M&eacut... See more
 
UCB [BE0003739530/UCB]   
[16/10/2021]

UCB : UCB Media Room: Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab

https://mb.cision.com/Public/18595/logo/86a99b25f755738d_org.jpg Update on U.S. FDA Review of Biologics License Application BLA for bim= ekizumab =C2=B7 The U.S. FDA has informed UCB via letter that the Agency was=C2=A0un= able to complete review of the BLA for bimekizumab by the PDUFA date and is= deferring action on the application =C2=B7 The Agency cited only the inability to... See more
 
UCB [BE0003739530/UCB]   
[16/10/2021]

UCB : UCB Media Room: Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab

https://mb.cision.com/Public/18595/logo/86a99b25f755738d_org.jpg Update on U.S. FDA Review of Biologics License Application BLA for bim= ekizumab =C2=B7 The U.S. FDA has informed UCB via letter that the Agency were unable= to complete review of the BLA for bimekizumab by the PDUFA date and is def= erring action on the application =C2=B7 The Agency cited only the inability to conduct... See more